Radius Health (NASDAQ: RDUS) reported Q4 EPS of ($0.66), $0.51 better than the analyst estimate of ($1.17). Revenue for the quarter came in at $34.4 million versus the consensus estimate of $33.01 million.

“I am very pleased with the continued strong performance of TYMLOS in the U.S. market. In 2019, we expect to continue expanding our market share for TYMLOS in the U.S. anabolic market and advancing our late-stage clinical pipeline with our pivotal elacestrant and abaloparatide-patch Phase 3 studies,” said Jesper Hoeiland, President and Chief Executive Officer of Radius.

GUIDANCE:

Radius Health sees FY2019 revenue of $155-175 million, versus the consensus of $172.09 million.

• With 2018 TYMLOS U.S. net sales reaching $99.2 million, Radius exceeded its 2018 full-year net sales guidance of $95 to $98 million. Radius’ 2018 year-end cash, cash equivalents and investments balance of $237 million was in line with its guidance for it to exceed $220 million.
• Radius maintains its 2019 financial guidance with full-year TYMLOS U.S. net sales expected to be between $155 to $175 million and its year-end cash, cash equivalents and investments balance expected to exceed $100 million.

For earnings history and earnings-related data on Radius Health (RDUS) click here.